[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603063":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":61,"collaborators":29,"id":64,"slug":29,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":29,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":29,"maxAge":29,"enrollmentInfo":71,"targetDuration":29,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":29,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Direct discontinuation group","PLACEBO_COMPARATOR","Sirolimus was gradually tapered and discontinued over a 2-month period.",[13],"Drug: Sirolimus",{"label":15,"type":16,"description":17,"interventionNames":18},"Low-dose treatment group","EXPERIMENTAL","Low-dose sirolimus treatment was administered for 6 months (with blood levels maintained at 2-5 ng\u002FmL), followed by gradual tapering and discontinuation over 2 months.",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Intermittent treatment group","Sirolimus was administered using a 3-days-on\u002F4-days-off weekly schedule for 6 months, followed by gradual tapering and discontinuation over 2 months.",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Sirolimus","Comparison of different sirolimus discontinuation strategies.",[9,20,15],null,[31],{"name":32,"affiliation":33,"role":34},"Yi Ji, PhD","Sichuan University West China Hospital","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":29,"email":39},"CONTACT","+862885423453","jijiyuanyuan@163.com",{"name":41,"role":37,"phone":42,"phoneExt":29,"email":43},"Jiangyuan Zhou, Doctor","+8613668491160","13668491160@163.com",[45],{"facility":46,"status":29,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041","China","CN",{"type":53,"coordinates":54},"Point",[55,56],104.06667,30.66667,{"lat":56,"lon":55},[59,60],{"name":32,"role":37,"phone":38,"phoneExt":29,"email":39},{"name":41,"role":37,"phone":29,"phoneExt":29,"email":43},{"type":34,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Yi Ji","MD, PhD","100603063",false,"NCT07131644","Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma","A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma","Inclusion Criteria:\n\n* KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.\n* With evaluable clinical or imaging parameters to monitor disease activity or recurrence.\n* Patients or their guardians are able to understand the study and provide written informed consent.\n* Hematologic and hepatic\u002Frenal function meet the safety criteria for drug administration.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.","ALL",{"count":72,"type":73},120,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.",[79],"Kaposiform Hemangioendothelioma",[79,26,81],"Discontinuation Strategies","NOT_YET_RECRUITING","2025-09-01",{"date":85,"type":86},"2025-09-08","ACTUAL",{"date":88,"type":73},"2025-09-13",{"date":90,"type":73},"2028-02-01",{"name":5,"class":6},1]